Gosset Ownership
Private
Employees
~9
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Dorian Therapeutics General Information
Dorian Therapeutics has developed a proprietary approach targeting cellular senescence at early stages to modulate stem cell pathways affected during aging. Their lead programs are in pre-clinical development and aim to counteract aging in degenerative diseases. No clinical results have been reported yet.
Contact Information
Primary Industry
Biotech
Corporate Office
San Carlos, California
United States
United States
Drug Pipeline
Pre-clinical
Key Partnerships
Y Combinator (accelerator/investor partnership)
Dorian Therapeutics Funding
No funding data available
To view Dorian Therapeutics's complete valuation and funding history, request access »